Considering efficacy and cost, where does ramucirumab fit in the management of metastatic colorectal cancer?

Oncologist

Volumn 20, Issue 9, 2015, Pages 981-982

  Goldstein, Dandaniel A ^a   El Rayes, Bassel F ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLFIRI REGIMEN; FOLFOX REGIMEN; OXALIPLATIN; RAMUCIRUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; CAMPTOTHECIN; FOLINIC ACID; MONOCLONAL ANTIBODY;

ARTICLE; CANCER GROWTH; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HUMAN; LUNG CANCER; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH CANCER; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; ECONOMICS; METASTASIS; PATHOLOGY; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG COSTS; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES;

EID: 84940646746     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0028     Document Type: Article

References (15)

1. Garon EB, Ciuleanu TE, Arrieta Oetal. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinumbased therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665-673.
2. Fuchs CS, Tomasek J, Yong CJ et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383:31-39.
3. Wilke H, Muro K,Van Cutsem E et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial. Lancet Oncol 2014;15:1224-1235.
4. Tabernero J, Yoshino T, Cohn AL et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during orafter first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499-508.
5. Bennouna J, Sastre J, Arnold D et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
6. Van Cutsem E, Tabernero J, Lakomy R et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30: 3499-3506.
7. Van Cutsem E, Köhne CH, L áng I et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as firstline treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-2019.
8. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 2011; 22:1535-1546.
9. Douillard JY, Oliner KS, Siena S et al. PanitumumabFOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-1034.
10. Oliner K, Douillard J-Y, Siena S et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). J Clin Oncol 2013;31 (suppl):3511a.
11. Schwartzberg LS, Rivera F, Karthaus M et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014;32: 2240-2247.
12. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15:1065-1075.
13. Fast Stats. Available at http://www.cdc.gov/nchs/fastats/
14. 14.2015 ASP drug pricing files. Available at http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/2015ASPFiles.html Accessed January 20, 2015
15. Bach PB, Saltz LB, Wittes RE. In cancer care, cost matters. New York Times. October 14, 2012. Available at http://www.nytimes.com/2012/10/15/opinion/a-hospital-says-no-to-an-11000-a-month-cancer-drug.html?_r50 Accessed January 20, 2015